HCV Treatment
ACH-1625 HCV Protease Inhibitor Starts Phase 2 Trial
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 08 July 2011 00:00
- Written by Achillion Pharmaceuticals
Achillion Pharmaceuticals recently announced that the first patients have started treatment in a Phase 2 clinical trial of the experimental HCV protease inhibitor ACH-1625 plus pegylated interferon and ribavirin.
Primary Care Docs Can Manage Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Tuesday, 05 July 2011 13:07
- Written by Liz Highleyman
The ECHO program showed that primary care clinicians can successfully treat underserved hepatitis C patients using video teleconferencing.
Telaprevir Improves Hepatitis C Treatment Response
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 28 June 2011 06:53
- Written by Liz Highleyman
The recently approved HCV protease telaprevir added to standard therapy increased cure rates for both previously untreated people and prior non-responders. 
HCV Drug TMC649128 Enters Phase 1b
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 28 June 2011 07:38
- Written by Medivir
A new HCV polymerase inhibitor, TMC649128, is now being tested in a Phase 1b trial, the first stage of evaluating safety and efficacy in a large number of patients.
Vertex Licenses Alios HCV Protease Inhibitors
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 17 June 2011 07:07
- Written by Vertex Pharmaceuticals
Vertex Pharmaceuticals and Alios BioPharma have agreed to collaborate on development of 2 novel nucleotide analog HCV NS5B polymerase inhibitor candidates, now at the preclinical stage.
Web Design and Development by